Asian Pacifc Journal of Cancer Prevention, Vol 15, 2014 3207 DOI:http://dx.doi.org/10.7314/APJCP.2014.15.7.3207 Infammatory Breast Cancer Asian Pac J Cancer Prev, 15 (7), 3207-3210 Introduction Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, characterized by the rapid appearance of erythema, edema, and peaud’ orange of breast as a result of occlusion of breast dermal lymphatics by tumor emboli (Kim et al., 2006). It accounts for 1% to 3% of all breast cancer cases in the west (Low et al., 2004). It is suggested, that along with a tissue diagnosis, peau d’orange should be involving one third or more of the breast for a diagnosis of IBC to be made (Chevallier B.,et al). Patients with IBC tend to progress rapidly and have a poor overall outcome (Harris et al., 2003). Multimodality therapy is now widely accepted as the standard of care for this disease with the reported 5-year overall survival (OS) rates ranging from 46% to 61% (Dawood et al., 2011). To date, there has been no published study from India on IBC. The aim of this study was to analyze the 1 Medical Oncology Department, 2 Surgical Oncology Department, 3 Radiation Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India *For correspondence: ajaygogia@gmail.com Abstract Background: Infammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterized by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d’orange appearance. It accounts for 1-3% of all newly diagnosed cases of breast cancer in the west. Data on IBC from India are lacking. The aim of our study was to assess the clinical-pathological parameters and outcome of IBC at, All India Institute of Medical Sciences, a large tertiary care centre. Materials and Methods: We screened 3,650 breast cancer cases registered from January 2004 to December 2012 and found 41 cases of IBC. Data included demographics as well as clinical, radiological and histopathological characteristics, and were collected from clinical case records using the International Classifcation of Diseases code (C-50). Patients who presented with IBC as a recurrence, or who had a neglected and advanced breast cancer that simulated an IBC were excluded from this study. Results: The median age was 45 years (range 23-66). The median duration of symptoms was 5 months. The American Joint Committee on Cancer stage (AJCC) distribution was Stage III - 26 and IV - 15 patients. Estrogen receptor (ER), progesterone receptor (PR) positivity and human epidermal growth factor receptor 2 (HER2/neu) positivity were 50%, 46% and 60%, respectively. Triple negativity was found in 15% of the cases. All the non metastatic IBC patients received anthracycline and/ or taxane based chemotherapy followed by modifed radical mastectomy , radiotherapy and hormonal therapy as indicated. Pathological complete remission rate was 15%. At a median follow-up of 30 months, the 3 year relapse free survival and overall survival were 30% and 40%respectively. Conclusion: IBC constituted 1.1% of all breast cancer patients at our centre. One third of these had metastatic disease at presentation. Hormone positivity and Her2 neu positivity were found in 50% and 60% of the cases, respectively. Keywords: Infammatory breast cancer - treatment - outcome - hormone charateristics - India RESEARCH ARTICLE Infammatory Breast Cancer: a Single Centre Analysis Ajay Gogia 1 *, Vinod Raina 1 , Suryanarayan Vishnu Deo 2 , Nootan Kumar Shukla 2 , Bidhu kalyan Mohanti 3 , Daya Nand Sharma 3 clinicopathologic characteristics and outcome of IBC in our patients. Materials and Methods We screened 3650 cases registered from January 2004 to December 2012 and found 41 cases of IBC with all base line parameters including hormonal profile. Patient’s records were obtained from the computer database using International Classifcation of Diseases code (C-50).The diagnosis of IBC was made clinically by a multidisciplinary team consisting of an onco- surgeon, a medical oncologist, and a radiation oncologist. Patients who had presented with IBC as a recurrence, or who had a neglected and advanced breast cancer that simulated an IBC were excluded from this study. All the patients were included in this study, who at least received two modality of treatment at our hospital. All the non metastatic IBC patients received neo adjuvant chemotherapy (NACT)